# The Efficacy and Safety of HIPEC Combined With PD-1 and SOX Chemotherapy for the Translational Treatment of GC or EGJC With PM

> **NCT06427252** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **The First Affiliated Hospital with Nanjing Medical University** · enrollment: 50 (estimated)

## Conditions studied

- Gastric Cancer, Metastatic

## Interventions

- **DRUG:** HIPEC
- **DRUG:** Systemic therapy

## Key facts

- **NCT ID:** NCT06427252
- **Lead sponsor:** The First Affiliated Hospital with Nanjing Medical University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2024-05-31
- **Primary completion:** 2026-05-31
- **Final completion:** 2027-05-31
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2025-07-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06427252

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06427252, "The Efficacy and Safety of HIPEC Combined With PD-1 and SOX Chemotherapy for the Translational Treatment of GC or EGJC With PM". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT06427252. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*